Halozyme Therapeutics (HALO) vs Bio-Techne (TECH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Halozyme Therapeutics (HALO) has outperformed Bio-Techne (TECH) over the past year, gaining 67.8% versus a gain of 22.5%. Over five years, HALO leads with a +193.4% price change compared with -41.7% for TECH. Halozyme Therapeutics is the larger company by market cap ($12.57 billion vs $11.37 billion), about 1.1 times the size.
On valuation, Halozyme Therapeutics trades at a lower forward P/E (10.6x vs 31.4x for Bio-Techne). Bio-Techne pays a dividend yielding 0.44%, while Halozyme Therapeutics does not currently pay one. Halozyme Therapeutics converts more of its revenue into profit, with a net margin of 22.7% versus 15.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HALO | TECH |
|---|---|---|
| Share price | $110.79 | $72.53 |
| Market cap | $12.57B | $11.37B |
| 1-day change | +0.98% | +0.14% |
| YTD return | +64.62% | +23.33% |
| 1-year return | +67.81% | +22.54% |
| 5-year return | +193.41% | -41.75% |
| P/E ratio (TTM) | 32.39 | 62.53 |
| Forward P/E | 10.59 | 31.36 |
| EPS (TTM) | $3.42 | $1.16 |
| Dividend yield | 0.00% | 0.44% |
| Annual dividend | $0.00 | $0.32 |
| Revenue (latest FY) | $1.40B | $1.22B |
| Revenue growth (YoY) | +37.55% | -0.38% |
| Net income (latest FY) | $316.89M | $181.86M |
| Gross margin | 83.62% | 65.77% |
| Operating margin | 33.58% | 20.73% |
| Net margin | 22.69% | 14.97% |
| 52-week high | $116.85 | $72.69 |
| 52-week low | $61.23 | $43.20 |
| Distance from 52-week high | -5.19% | -0.22% |
| Analyst consensus | buy | hold |
| Avg. price target upside | -10.14% | -2.80% |
| Average volume | 2.17M | 3.08M |
| Shares outstanding | 113.50M | 156.82M |
| Employees | 423 | 3,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HALO has outperformed TECH by 45.3 percentage points over the past year.
- Bio-Techne trades at a higher earnings multiple (62.5x vs 32.4x trailing P/E).
- Halozyme Therapeutics is more profitable, keeping 22.7 cents of every revenue dollar as net income versus 15.0 cents for Bio-Techne.
- Halozyme Therapeutics grew revenue faster in its latest fiscal year (+37.55% vs -0.38%).
About Halozyme Therapeutics
HALO stock →Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 423 employees
About Bio-Techne
TECH stock →Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 3,000 employees
HALO vs TECH FAQ
Which is bigger, Halozyme Therapeutics or Bio-Techne?
Halozyme Therapeutics (HALO) is larger, with a market capitalization of $12.57B compared with $11.37B for Bio-Techne (TECH).
Which stock has performed better over the past year, HALO or TECH?
HALO returned +67.81% over the past 12 months, compared with +22.54% for TECH (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, HALO or TECH?
HALO has the lower trailing P/E at 32.4, versus 62.5 for TECH. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Halozyme Therapeutics or Bio-Techne?
Bio-Techne pays a dividend yielding 0.44%, while Halozyme Therapeutics does not currently pay a regular dividend.
Are Halozyme Therapeutics and Bio-Techne in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.